p53 polymorphisms: cancer implications
- PMID: 19165225
- DOI: 10.1038/nrc2584
p53 polymorphisms: cancer implications
Abstract
The normal functioning of p53 is a potent barrier to cancer. Tumour-associated mutations in TP53, typically single nucleotide substitutions in the coding sequence, are a hallmark of most human cancers and cause dramatic defects in p53 function. By contrast, only a small fraction, if any, of the >200 naturally occurring sequence variations (single nucleotide polymorphisms, SNPs) of TP53 in human populations are expected to cause measurable perturbation of p53 function. Polymorphisms in the TP53 locus that might have cancer-related phenotypical manifestations are the subject of this Review. Polymorphic variants of other genes in the p53 pathway, such as MDM2, which might have biological consequences either individually or in combination with p53 variants are also discussed.
Similar articles
-
Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.J Cell Mol Med. 2009 Mar;13(3):440-53. doi: 10.1111/j.1582-4934.2008.00634.x. J Cell Mol Med. 2009. PMID: 19379143 Free PMC article. Review.
-
p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.Fam Cancer. 2018 Apr;17(2):269-274. doi: 10.1007/s10689-017-0028-4. Fam Cancer. 2018. PMID: 28756477
-
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.Cell. 2004 Nov 24;119(5):591-602. doi: 10.1016/j.cell.2004.11.022. Cell. 2004. PMID: 15550242
-
The Enigma of p53.Cold Spring Harb Symp Quant Biol. 2016;81:37-40. doi: 10.1101/sqb.2016.81.031062. Epub 2016 Dec 8. Cold Spring Harb Symp Quant Biol. 2016. PMID: 27932563 Review.
-
The p53 mutation "gradient effect" and its clinical implications.J Cell Physiol. 2007 Nov;213(2):370-3. doi: 10.1002/jcp.21217. J Cell Physiol. 2007. PMID: 17671971 Review.
Cited by
-
Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.Clin Transl Oncol. 2016 Jan;18(1):73-81. doi: 10.1007/s12094-015-1338-3. Epub 2015 Jul 25. Clin Transl Oncol. 2016. PMID: 26209050
-
Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population.Tumour Biol. 2015 Aug;36(8):6369-74. doi: 10.1007/s13277-015-3324-3. Epub 2015 Mar 25. Tumour Biol. 2015. PMID: 25801242
-
The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.Physiol Genomics. 2012 Feb 27;44(4):237-44. doi: 10.1152/physiolgenomics.00141.2011. Epub 2012 Jan 3. Physiol Genomics. 2012. PMID: 22214600 Free PMC article. Review.
-
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.Nat Rev Drug Discov. 2010 Aug;9(8):643-60. doi: 10.1038/nrd3184. Nat Rev Drug Discov. 2010. PMID: 20671765 Review.
-
TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.Med Oncol. 2011 Dec;28(4):1129-35. doi: 10.1007/s12032-010-9597-x. Epub 2010 Jun 15. Med Oncol. 2011. PMID: 20552298
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous